These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 21767511)

  • 1. The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.
    Jóna A; Khaskhely N; Buglio D; Shafer JA; Derenzini E; Bollard CM; Medeiros LJ; Illés A; Ji Y; Younes A
    Exp Hematol; 2011 Oct; 39(10):1007-1017.e1. PubMed ID: 21767511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia/lymphoma.
    Kunami N; Katsuya H; Nogami R; Ishitsuka K; Tamura K
    Anticancer Res; 2014 Oct; 34(10):5287-94. PubMed ID: 25275021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.
    Buglio D; Mamidipudi V; Khaskhely NM; Brady H; Heise C; Besterman J; Martell RE; MacBeth K; Younes A
    Br J Haematol; 2010 Nov; 151(4):387-96. PubMed ID: 20880107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
    Denlinger CE; Rundall BK; Keller MD; Jones DR
    Ann Thorac Surg; 2004 Oct; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines.
    Premkumar DR; Jane EP; DiDomenico JD; Vukmer NA; Agostino NR; Pollack IF
    J Pharmacol Exp Ther; 2012 Jun; 341(3):859-72. PubMed ID: 22393246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
    Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F
    Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.
    Bhalla S; Balasubramanian S; David K; Sirisawad M; Buggy J; Mauro L; Prachand S; Miller R; Gordon LI; Evens AM
    Clin Cancer Res; 2009 May; 15(10):3354-65. PubMed ID: 19417023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
    Frys S; Simons Z; Hu Q; Barth MJ; Gu JJ; Mavis C; Skitzki J; Song L; Czuczman MS; Hernandez-Ilizaliturri FJ
    Br J Haematol; 2015 May; 169(4):506-19. PubMed ID: 25712263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.
    Paoluzzi L; Gonen M; Bhagat G; Furman RR; Gardner JR; Scotto L; Gueorguiev VD; Heaney ML; Manova K; O'Connor OA
    Blood; 2008 Oct; 112(7):2906-16. PubMed ID: 18591385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional inhibition of BCL2 is needed to increase the susceptibility to apoptosis to SMO inhibitors in diffuse large B-cell lymphoma of germinal center subtype.
    Kunkalla K; Liu Y; Qu C; Leventaki V; Agarwal NK; Singh RR; Vega F
    Ann Hematol; 2013 Jun; 92(6):777-87. PubMed ID: 23370596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling.
    Feng R; Ma H; Hassig CA; Payne JE; Smith ND; Mapara MY; Hager JH; Lentzsch S
    Mol Cancer Ther; 2008 Jun; 7(6):1494-505. PubMed ID: 18566220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
    Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
    Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.
    Hui KF; Leung YY; Yeung PL; Middeldorp JM; Chiang AK
    Br J Haematol; 2014 Dec; 167(5):639-50. PubMed ID: 25155625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1.
    Chen S; Dai Y; Pei XY; Grant S
    Mol Cell Biol; 2009 Dec; 29(23):6149-69. PubMed ID: 19805519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New potential anti-cancer agents synergize with bortezomib and ABT-737 against prostate cancer.
    Pandit B; Gartel AL
    Prostate; 2010 Jun; 70(8):825-33. PubMed ID: 20058240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo.
    Huang H; Liu N; Yang C; Liao S; Guo H; Zhao K; Li X; Liu S; Guan L; Liu C; Xu L; Zhang C; Song W; Li B; Tang P; Dou QP; Liu J
    PLoS One; 2012; 7(12):e52576. PubMed ID: 23285100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells.
    Miller CP; Rudra S; Keating MJ; Wierda WG; Palladino M; Chandra J
    Blood; 2009 Apr; 113(18):4289-99. PubMed ID: 19182209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines.
    Batova A; Shao LE; Diccianni MB; Yu AL; Tanaka T; Rephaeli A; Nudelman A; Yu J
    Blood; 2002 Nov; 100(9):3319-24. PubMed ID: 12384433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
    Rooswinkel RW; van de Kooij B; Verheij M; Borst J
    Cell Death Dis; 2012 Aug; 3(8):e366. PubMed ID: 22875003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.